LUNG Pulmonx Corp
Price (delayed)
$6.82
Market cap
$271.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.44
Enterprise value
$256.72M
Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment
Highlights
The revenue has grown by 22% YoY and by 6% from the previous quarter
Pulmonx's gross profit has increased by 22% YoY and by 5% from the previous quarter
Pulmonx's debt has increased by 36% YoY
The quick ratio is down by 28% since the previous quarter and by 16% year-on-year
Key stats
What are the main financial stats of LUNG
Market
Valuations
Earnings
Shares outstanding
39.8M
Market cap
$271.41M
Enterprise value
$256.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.14
Price to sales (P/S)
3.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.06
Revenue
$83.79M
Gross profit
$62M
Operating income
-$57.7M
Net income
-$56.39M
EBIT
-$52.39M
EBITDA
-$49.05M
Free cash flow
-$32.98M
Per share
Balance sheet
Liquidity
EPS
-$1.44
EPS diluted
-$1.44
Free cash flow per share
-$0.84
Book value per share
$2.17
Revenue per share
$2.14
TBVPS
$4.1
Total assets
$162.85M
Total liabilities
$77.04M
Debt
$56.47M
Equity
$85.81M
Working capital
$111.81M
Debt to equity
0.66
Current ratio
5.58
Quick ratio
4.7
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
-58.5%
Gross margin
74%
Net margin
-67.3%
Operating margin
-68.9%
Return on assets
-33.8%
Return on equity
-57.6%
Return on invested capital
-40.5%
Return on capital employed
-37.8%
Return on sales
-62.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LUNG stock price
How has the Pulmonx stock price performed over time
Intraday
-0.73%
1 week
1.19%
1 month
-20.88%
1 year
-19.86%
YTD
0.44%
QTD
1.34%
Financial performance
How have Pulmonx's revenue and profit performed over time
Revenue
$83.79M
Gross profit
$62M
Operating income
-$57.7M
Net income
-$56.39M
Gross margin
74%
Net margin
-67.3%
Pulmonx's net margin has increased by 24% YoY and by 7% QoQ
Pulmonx's operating margin has increased by 24% YoY and by 6% from the previous quarter
The revenue has grown by 22% YoY and by 6% from the previous quarter
Pulmonx's gross profit has increased by 22% YoY and by 5% from the previous quarter
Growth
What is Pulmonx's growth rate over time
Valuation
What is Pulmonx stock price valuation
P/E
N/A
P/B
3.14
P/S
3.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.06
Pulmonx's EPS has increased by 10% YoY and by 2% from the previous quarter
The P/B is 31% lower than the 5-year quarterly average of 4.6
The company's equity fell by 27% YoY and by 9% QoQ
The price to sales (P/S) is 78% less than the 5-year quarterly average of 14.8 and 18% less than the last 4 quarters average of 3.9
The revenue has grown by 22% YoY and by 6% from the previous quarter
Efficiency
How efficient is Pulmonx business performance
Pulmonx's ROS has increased by 25% YoY and by 6% from the previous quarter
The company's return on equity fell by 24% YoY and by 7% QoQ
LUNG's return on invested capital is up by 21% year-on-year and by 2.9% since the previous quarter
The ROA fell by 5% YoY
Dividends
What is LUNG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LUNG.
Financial health
How did Pulmonx financials performed over time
Pulmonx's total assets is 111% more than its total liabilities
Pulmonx's total liabilities has increased by 30% YoY and by 4.9% from the previous quarter
Pulmonx's current ratio has decreased by 28% from the previous quarter and by 14% YoY
Pulmonx's debt is 34% lower than its equity
The debt to equity has surged by 89% year-on-year and by 12% since the previous quarter
Pulmonx's debt has increased by 36% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.